The Evolution of HTA in Emerging Markets Health-Care ... - TREE

More documents

Recommendations

Info

OHE Consulting Report for PhRMA 5 January 2011 Section 8 sets out our overall findings including recommendations to inform PhRMA’s policy position with respect to the use of HTA in emerging economies and to the three countries Brazil, China and Taiwan in particular. 2.3 Acknowledgements This project has been undertaken by OHE with the assistance of Lou Garrison and colleagues at VeriTech Corporation and the University of Washington, Seattle, and our local researchers Vanessa Teich, Michael Qin, and Ivy Tsai and who have undertaken research and interviews in Brazil, China, and Taiwan, respectively. 18
OHE Consulting Report for PhRMA 5 January 2011 3 Terms of Reference This project was commissioned to inform the development of policy positions with respect to the role (if any) for Health Technology Assessment (HTA) in emerging markets. PhRMA’s policy stance is not to promote the use of HTA where it doesn't exist but to be prepared with an appropriate response to engage and shape HTA when it is put forward by a payer. The purpose of the study is to help inform such an approach. The objectives of the study are as follows: a) To develop: iii) iv) categorisation of health care systems which can be accepted by key institutions and experts in the field (WHO, World Bank and academia); a categorisation of types of HTA using definitions recognised by practitioners in the field. Inevitably these are based on the experiences of high income countries, but can be expressed in a form that can fit into policy development in relation to the current and future healthcare systems of low and middle income countries; b) To combine these two strands to convey the key message that the relevance and positioning of any role for HTA in a health care system depends on the development stage and structure of that health care system; c) To use the approach above to analyse current approaches to HTA, and options for planned development of HTA, in three emerging markets: Brazil, China and Taiwan. The outputs of this study are intended to enable PhRMA to: d) develop its public policy positions within a credible framework relating any potential use of HTA proposed by payers to the evolution of health care systems; e) develop an appropriate response within this framework to engage and shape HTA when it is put forward by a payer in these three countries; and f) begin to build a network of contacts within the three countries to help take its approach forward. 19
Page 1 and 2: Consulting Report 1 The Evolution
Page 3 and 4: OHE Consulting Report for PhRMA 5 J
Page 17: OHE Consulting Report for PhRMA 5 J
Page 69 and 70:
OHE Consulting Report for PhRMA 5 J
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119:
show all

The Evolution of HTA in Emerging Markets Health-Care ... - TREE

Create successful ePaper yourself

Delete template?

Save as template?